The clinical trial investigates the noninvasive imaging of S1P1 using the radiotracer [C-11]-CS1P1, which is critical for understanding its role in neuroinflammation and neurodegeneration, particularly in multiple sclerosis (MS). The relevance of S1P1 has been underscored by the FDA approval of fingolimod (FTY720) for RR-MS, indicating a growing market for S1P1-targeted therapies and diagnostics. The successful development of [C-11]-CS1P1 could position the sponsor favorably within the neuroimaging market, potentially leading to partnerships with pharmaceutical companies focused on MS and other neurodegenerative diseases. Competitive implications include the need to monitor other imaging agents targeting similar pathways and the potential for collaboration with entities developing S1P1 modulators.